Open Access
Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management
Axel Dignass,James O. Lindsay,Andreas Sturm,Alastair Windsor,Jean-Frédéric Colombel,Mathieu Allez,G. D'Haens,André D'Hoore,Gerassimos J. Mantzaris,Gottfried Novacek,Tom Øresland,W. Reinisch,Miquel Sans,Eduard F. Stange,Severine Vermeire,Simon Travis,Gert A. Van Assche +16 more
Reads0
Chats0
TLDR
In this article, the authors presented a study of Gastroenterology at the University of Toronto and University of Leuven (Belgium) with the aim of identifying the cause of colorectal cancer.Abstract:
,2,3Department of Medicine 1, Agaplesion Markus Hospital, Wilhelm-Epstein-Str. 4, D-60431 Frankfurt/Main, GermanyDivision of Gastroenterology, Department of Medicine, MtSinai Hospital and University Health Network;University of Toronto, 600 University Avenue, Toronto, ON, Canada M5G 1X5 and University of Leuven, BelgiumReceived 26 August 2012; accepted 3 September 2012KEYWORDSread more
Citations
More filters
Journal ArticleDOI
The gut microbiota and host health: a new clinical frontier
Julian R. Marchesi,David H. Adams,Francesca Fava,Gerben D. A. Hermes,Gideon M. Hirschfield,Georgina L. Hold,Mohammed Nabil Quraishi,James Kinross,Hauke Smidt,Kieran Tuohy,Linda V. Thomas,Erwin G. Zoetendal,Ailsa Hart +12 more
TL;DR: The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidence relating to antibiotics, probiotics, prebiotics, polyphenols and faecal microbiota transplantation.
Journal ArticleDOI
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.
Fernando Magro,Paolo Gionchetti,Rami Eliakim,Sandro Ardizzone,Alessandro Armuzzi,Manuel Barreiro-de Acosta,Johan Burisch,Krisztina Gecse,Ailsa Hart,Pieter Hindryckx,Cord Langner,Jimmy K. Limdi,Gianluca Pellino,Edyta Zagórowicz,Tim Raine,Marcus Harbord,Florian Rieder +16 more
TL;DR: This research presents a meta-analyses of Gastroenterology and Hepatology at the cellular and molecular level, which shows clear trends in the development of immune-oncology-metabolical pathways towards “clinically checkpoints”.
Journal ArticleDOI
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Sudabeh Alatab,Sadaf G. Sepanlou,Kevin Ikuta,Homayoon Vahedi,Catherine Bisignano,Saeid Safiri,Anahita Sadeghi,Molly R Nixon,Amir Abdoli,Hassan Abolhassani,Vahid Alipour,Majid A Almadi,Amir Almasi-Hashiani,Amir Anushiravani,Jalal Arabloo,Suleman Atique,Ashish Awasthi,Alaa Badawi,Atif Amin Baig,Neeraj Bhala,Ali Bijani,Antonio Biondi,Antonio Maria Borzì,Kristin E Burke,Félix Carvalho,Ahmad Daryani,Manisha Dubey,Aziz Eftekhari,Eduarda Fernandes,João C. Fernandes,Florian Fischer,Arvin Haj-Mirzaian,Arya Haj-Mirzaian,Amir Hasanzadeh,Maryam Hashemian,Simon I. Hay,Chi L Hoang,Mowafa Househ,Olayinka Stephen Ilesanmi,Nader Jafari Balalami,Spencer L. James,Andre Pascal Kengne,Masoud M Malekzadeh,Shahin Merat,Tuomo J. Meretoja,Tomislav Mestrovic,Erkin M. Mirrakhimov,Hamid Reza Mirzaei,Karzan Abdulmuhsin Mohammad,Ali H. Mokdad,Lorenzo Monasta,Ionut Negoi,Trang Huyen Nguyen,Cuong Tat Nguyen,Akram Pourshams,Hossein Poustchi,Mohammad Rabiee,Navid Rabiee,Kiana Ramezanzadeh,David Laith Rawaf,Salman Rawaf,Nima Rezaei,Stephen R. Robinson,Luca Ronfani,Sonia Saxena,Masood Sepehrimanesh,Masood Ali Shaikh,Zeinab Sharafi,Mehdi Sharif,Soraya Siabani,Ali Reza Sima,Jasvinder A. Singh,Amin Soheili,Rasoul Sotoudehmanesh,Hafiz Ansar Rasul Suleria,Berhe Etsay Tesfay,Bach Xuan Tran,Derrick Tsoi,Marco Vacante,Adam Belay Wondmieneh,Afshin Zarghi,Zhi-Jiang Zhang,Mae Dirac,Reza Malekzadeh,Mohsen Naghavi +84 more
TL;DR: The prevalence of IBD increased substantially in many regions from 1990 to 2017, which might pose a substantial social and economic burden on governments and health systems in the coming years.
Journal ArticleDOI
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn,Chinyu Su,Bruce E. Sands,Geert R. D'Haens,Severine Vermeire,Stefan Schreiber,Silvio Danese,Brian G. Feagan,Walter Reinisch,Wojciech Niezychowski,Gary S. Friedman,Nervin Lawendy,Dahong Yu,Deborah A Woodworth,Arnab Mukherjee,Haiying Zhang,Paul J. Healey,Julián Panés +17 more
TL;DR: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo and was associated with increased lipid levels.
Journal ArticleDOI
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros,Ahmad A. Tarhini,Emilie Routier,Olivier Lambotte,Francois Leroy Ladurie,Franck Carbonnel,Hassane Izzeddine,Aurélien Marabelle,Stéphane Champiat,Armandine Berdelou,Emilie Lanoy,M. Texier,C. Libenciuc,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Jean-Charles Soria,Jean-Charles Soria,Jean-Charles Soria,Christine Mateus,Caroline Robert,Caroline Robert,Caroline Robert +21 more
TL;DR: The authors describe the adverse event profile of checkpoint inhibitors targeting CTLA-4 and PD-1, used both as monotherapies and in combination and aim to provide some general guidelines, based upon the mechanisms of action of these therapies and on the management of these immune-related adverse events.
References
More filters
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg,Jack Satsangi,Tariq Ahmad,Ian D. Arnott,Charles N. Bernstein,Steven R. Brant,Renzo Caprilli,Jean-Frederic Colombel,Christoph Gasche,Karel Geboes,Derek P. Jewell,Amir Karban,Edward V. Loftus,A. Salvador Peña,Robert H. Riddell,David B. Sachar,Stefan Schreiber,A. Hillary Steinhart,Stephan R. Targan,Severine Vermeire,Bryan F. Warren +20 more
TL;DR: The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Journal ArticleDOI
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Jean-Frederic Colombel,William J. Sandborn,Walter Reinisch,Gerassimos J. Mantzaris,Asher Kornbluth,Daniel Rachmilewitz,Simon Lichtiger,Robert H. Diamond,Delma L. Broussard,Kezhen L. Tang,C. Janneke van der Woude,Paul Rutgeerts +11 more
TL;DR: Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Journal ArticleDOI
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G. Feagan,Paul Rutgeerts,Bruce E. Sands,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,William J. Sandborn,Gert Van Assche,Jeffrey Axler,Hyo-Jong Kim,Silvio Danese,I. Fox,Catherine Milch,Serap Sankoh,Tim Wyant,Jingcan Xu,Asit Parikh +16 more
TL;DR: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.